Jazz Pharmaceuticals

NASDAQ: JAZZ · Real-Time Price · USD
116.67
0.00 (0.00%)
At close: Aug 15, 2025, 3:04 PM

Jazz Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
4.07B 3.83B 3.66B 3.09B
Cost of Revenue
445.71M 435.58M 267.13M 440.76M
Gross Profit
3.62B 3.4B 3.39B 2.65B
Operating Income
716.63M 578.58M -65.53M 170.28M
Interest Income
n/a n/a n/a n/a
Pretax Income
470.35M 294.92M -382.7M -112.84M
Net Income
560.12M 414.83M -224.06M -328.95M
Selling & General & Admin
1.39B 1.34B 1.42B 1.45B
Research & Development
884M 849.66M 590.45M 505.75M
Other Expenses
637.31M 627.28M 1.45B 525.77M
Operating Expenses
2.91B 2.82B 3.46B 2.48B
Interest Expense
238.1M 289.44M 288.24M 278.77M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
3.35B 3.26B 3.72B 2.92B
Income Tax Expense
-91.43M -119.91M -158.65M 216.12M
Shares Outstanding (Basic)
61.84M 63.29M 62.54M 59.69M
Shares Outstanding (Diluted)
66.01M 72.07M 62.54M 59.69M
EPS (Basic)
9.06 6.55 -3.58 -5.51
EPS (Diluted)
8.65 6.10 -3.58 -5.51
EBITDA
1.37B 1.23B 553.78M 718.41M
EBIT
708.45M 587.37M -75.69M 165.93M
Depreciation & Amortization
660.07M 638.7M 629.47M 552.48M